# LITESPARK-012 (NCT04736706)

> A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04736706
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Carcinoma, Renal Cell
- Interventions: Pembrolizumab; Belzutifan; Pembrolizumab/Quavonlimab; Lenvatinib
- Enrollment: 1688
- Primary outcome: Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
- Primary outcome: Overall Survival (OS)

## Indexed commentary on LITESPARK-012 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 73
- Podcasts: 6
- YouTube: 3
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=litespark-012-nct04736706

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04736706", "email": "<work email>"}; the inbox owner confirms by the emailed link.